NYSE:ENFN Enfusion (ENFN) Stock Forecast, Price & News $7.88 +0.08 (+1.03%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$7.79▼$8.0350-Day Range$7.54▼$10.5052-Week Range$7.37▼$16.76Volume571,676 shsAverage Volume404,192 shsMarket Capitalization$916.37 millionP/E Ratio197.05Dividend YieldN/APrice Target$11.08 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Enfusion MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside40.7% Upside$11.08 Price TargetShort InterestHealthy4.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 6 Articles This WeekInsider TradingSelling Shares$11.56 M Sold Last QuarterProj. Earnings Growth66.67%From $0.12 to $0.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.56 out of 5 starsComputer And Technology Sector108th out of 623 stocksPrepackaged Software Industry28th out of 217 stocks 3.0 Analyst's Opinion Consensus RatingEnfusion has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.08, Enfusion has a forecasted upside of 40.7% from its current price of $7.88.Amount of Analyst CoverageEnfusion has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.47% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enfusion has recently decreased by 0.75%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEnfusion does not currently pay a dividend.Dividend GrowthEnfusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENFN. Previous Next 1.7 News and Social Media Coverage News SentimentEnfusion has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Enfusion this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ENFN on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Enfusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,555,367.00 in company stock.Percentage Held by Insiders40.10% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions49.38% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Enfusion are expected to grow by 66.67% in the coming year, from $0.12 to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enfusion is 197.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 132.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Enfusion is 197.05, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 339.95.Price to Earnings Growth RatioEnfusion has a PEG Ratio of 1.32. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEnfusion has a P/B Ratio of 9.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enfusion (NYSE:ENFN) StockEnfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.Read More Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address ENFN Stock News HeadlinesMay 26, 2023 | americanbankingnews.comEnfusion (NYSE:ENFN) Stock Price Up 2.7%May 25, 2023 | businesswire.comEnfusion To Present at the 43 rd Annual William Blair Growth Stock ConferenceMay 28, 2023 | Behind the Markets (Ad)NOTICE: Your retirement is in immediate dangerSoon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>May 25, 2023 | finance.yahoo.comEnfusion To Present at the 43rd Annual William Blair Growth Stock ConferenceMay 22, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Hold Rating on Enfusion (ENFN)May 22, 2023 | americanbankingnews.comEnfusion (NYSE:ENFN) Price Target Lowered to $9.00 at Piper SandlerMay 11, 2023 | seekingalpha.comEnfusion, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 9, 2023 | finance.yahoo.comBull Of The Day: Enfusion (ENFN)May 28, 2023 | Behind the Markets (Ad)NOTICE: Your retirement is in immediate dangerSoon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>May 9, 2023 | finance.yahoo.comEnfusion, Inc. (ENFN) Q1 Earnings Meet EstimatesMay 8, 2023 | americanbankingnews.comEnfusion (ENFN) to Release Quarterly Earnings on TuesdayMay 5, 2023 | finance.yahoo.comEnfusion (ENFN) to Report Q1 Earnings: What's in the Offing?May 5, 2023 | finance.yahoo.comFewer Investors Than Expected Jumping On Enfusion, Inc. (NYSE:ENFN)May 2, 2023 | msn.comEnfusion, Inc. (ENFN) Flat As Market Sinks: What You Should KnowMay 2, 2023 | finance.yahoo.comEnfusion, Inc. (ENFN) Q1 Earnings Preview: What's in the Cards?May 2, 2023 | finance.yahoo.comGlobal SaaS Leader Zone & Co Appoints Seasoned FinTech Exec Thomas Kim as New CEOApril 26, 2023 | finanznachrichten.deEnfusion, Inc.: Enfusion Announces Date of First Quarter 2023 ResultsApril 25, 2023 | finance.yahoo.comBears are Losing Control Over Enfusion, Inc. (ENFN), Here's Why It's a 'Buy' NowApril 24, 2023 | finance.yahoo.comEnfusion, Inc. (ENFN) Outpaces Stock Market Gains: What You Should KnowApril 21, 2023 | finance.yahoo.comAfter Plunging -14.72% in 4 Weeks, Here's Why the Trend Might Reverse for Enfusion, Inc. (ENFN)April 20, 2023 | finance.yahoo.comEnfusion Announces Date of First Quarter 2023 ResultsApril 20, 2023 | americanbankingnews.comEnfusion, Inc. (NYSE:ENFN) CTO Dan Groman Sells 3,877 Shares of StockApril 15, 2023 | americanbankingnews.comEnfusion (NYSE:ENFN) Sees Strong Trading VolumeApril 9, 2023 | seekingalpha.comEnfusion: Still Very AttractiveApril 7, 2023 | finance.yahoo.comEnfusion, Inc. (ENFN) Interactive Stock Chart - Yahoo FinanceApril 6, 2023 | finance.yahoo.comEnfusion Announces Partnership With Leading Risk Management Provider QontigoApril 3, 2023 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About EnfusionSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address ENFN Company Calendar Last Earnings3/07/2023Today5/27/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Prepackaged software Sub-IndustryN/A SectorComputer and Technology Current SymbolNYSE:ENFN CUSIPN/A CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees1,006Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.08 High Stock Price Forecast$14.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+40.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio197.05 Forward P/E Ratio65.67 P/E Growth1.32Net Income$-7,650,000.00 Net Margins1.81% Pretax Margin3.36% Return on Equity2.81% Return on Assets2.42% Debt Debt-to-Equity RatioN/A Current Ratio6.32 Quick Ratio6.32 Sales & Book Value Annual Sales$150.35 million Price / Sales6.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.85 per share Price / Book9.27Miscellaneous Outstanding Shares116,290,000Free Float69,655,000Market Cap$916.37 million OptionableNot Optionable Beta0.43 Key ExecutivesMr. Oleg Movchan (Age 49)CEO & Director Mr. Stephen MalherbeManaging PartnerMr. Bradley Herring (Age 52)Chief Financial Officer Mr. Michael BerryChief Operating OfficerMr. Daniel Groman (Age 34)Chief Technology Officer Mr. Brian MurphyInvestorMs. Lorelei M. Skillman (Age 53)Chief Marketing & Communications Officer Ms. Bronwen Bastone (Age 50)Chief People Officer Mr. Kabir KohliMD of Managed Services Solutioning & Global Head of Client ServicesMr. Joseph DefeoGlobal Head of Managed Services ProductionMore ExecutivesKey CompetitorsAvid TechnologyNASDAQ:AVIDCouchbaseNASDAQ:BASEEverbridgeNASDAQ:EVBGSecureWorksNASDAQ:SCWXWalkMeNASDAQ:WKMEView All CompetitorsInsiders & InstitutionsRoyce & Associates LPSold 27,400 shares on 5/23/2023Ownership: 0.012%Putnam Investments LLCSold 1,586 shares on 5/22/2023Ownership: 0.032%New York State Common Retirement FundBought 533,198 shares on 5/18/2023Ownership: 1.050%JPMorgan Chase & Co.Bought 333,982 shares on 5/18/2023Ownership: 0.309%State Street CorpSold 6,623 shares on 5/16/2023Ownership: 0.454%View All Insider TransactionsView All Institutional Transactions ENFN Stock - Frequently Asked Questions Should I buy or sell Enfusion stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ENFN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENFN, but not buy additional shares or sell existing shares. View ENFN analyst ratings or view top-rated stocks. What is Enfusion's stock price forecast for 2023? 5 brokers have issued 1 year target prices for Enfusion's stock. Their ENFN share price forecasts range from $9.00 to $14.00. On average, they anticipate the company's share price to reach $11.08 in the next twelve months. This suggests a possible upside of 40.7% from the stock's current price. View analysts price targets for ENFN or view top-rated stocks among Wall Street analysts. How have ENFN shares performed in 2023? Enfusion's stock was trading at $9.67 on January 1st, 2023. Since then, ENFN shares have decreased by 18.5% and is now trading at $7.88. View the best growth stocks for 2023 here. When is Enfusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our ENFN earnings forecast. How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) posted its quarterly earnings results on Tuesday, March, 7th. The company reported $0.01 EPS for the quarter. The business had revenue of $40.52 million for the quarter, compared to analysts' expectations of $39.88 million. Enfusion had a net margin of 1.81% and a trailing twelve-month return on equity of 2.81%. What ETF holds Enfusion's stock ? Direxion Daily Cloud Computing Bull 2x holds 378 shares of ENFN stock, representing 0.05% of its portfolio. What guidance has Enfusion issued on next quarter's earnings? Enfusion issued an update on its FY 2023 earnings guidance on Wednesday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $185.00 million-$190.00 million, compared to the consensus revenue estimate of $188.13 million. When did Enfusion IPO? (ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share. What is Enfusion's stock symbol? Enfusion trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENFN." Who are Enfusion's major shareholders? Enfusion's stock is owned by a number of institutional and retail investors. Top institutional investors include Brown Capital Management LLC (7.26%), BlackRock Inc. (1.35%), New York State Common Retirement Fund (1.05%), New York State Common Retirement Fund (1.05%), Wasatch Advisors LP (0.48%) and State Street Corp (0.45%). Insiders that own company stock include Dan Groman, Hillhouse Investment Managemen, Roy Luo, Stephen Malherbe and Tarek Hammoud. View institutional ownership trends. How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enfusion's stock price today? One share of ENFN stock can currently be purchased for approximately $7.88. How much money does Enfusion make? Enfusion (NYSE:ENFN) has a market capitalization of $916.37 million and generates $150.35 million in revenue each year. The company earns $-7,650,000.00 in net income (profit) each year or $0.04 on an earnings per share basis. How many employees does Enfusion have? The company employs 1,006 workers across the globe. How can I contact Enfusion? The official website for the company is www.enfusion.com. The company can be reached via phone at 312-253-9800 or via email at brian.murphy@icrinc.com. This page (NYSE:ENFN) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.